Your browser is no longer supported. Please, upgrade your browser.
Settings
VBLT Vascular Biogenics Ltd. daily Stock Chart
VBLT [NASD]
Vascular Biogenics Ltd.
Index- P/E- EPS (ttm)-0.67 Insider Own30.31% Shs Outstand26.24M Perf Week-10.46%
Market Cap179.74M Forward P/E- EPS next Y-0.76 Insider Trans0.00% Shs Float19.11M Perf Month14.17%
Income-17.90M PEG- EPS next Q-0.20 Inst Own32.20% Short Float3.18% Perf Quarter37.00%
Sales- P/S- EPS this Y12.60% Inst Trans-2.72% Short Ratio2.43 Perf Half Y16.10%
Book/sh1.30 P/B5.27 EPS next Y5.00% ROA-39.50% Target Price13.75 Perf Year38.38%
Cash/sh1.29 P/C5.32 EPS next 5Y- ROE-44.10% 52W Range3.90 - 9.05 Perf YTD41.24%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-24.31% Beta-
Dividend %- Quick Ratio6.50 Sales past 5Y- Gross Margin- 52W Low75.64% ATR0.72
Employees27 Current Ratio6.50 Sales Q/Q- Oper. Margin- RSI (14)48.98 Volatility13.43% 8.40%
OptionableYes Debt/Eq0.00 EPS Q/Q-30.00% Profit Margin- Rel Volume12.26 Prev Close9.00
ShortableYes LT Debt/Eq0.00 EarningsNov 14 BMO Payout- Avg Volume250.13K Price6.85
Recom2.00 SMA200.46% SMA509.10% SMA20025.05% Volume3,066,763 Change-23.89%
Nov-06-17Reiterated Chardan Capital Markets Buy $20 → $25
Jun-28-16Initiated H.C. Wainwright Buy $11
Nov-09-15Initiated Piper Jaffray Overweight
Oct-23-15Reiterated Chardan Capital Markets Buy $25 → $27.50
Sep-28-15Reiterated ROTH Capital Buy $13 → $22
Sep-22-15Initiated Chardan Capital Markets Buy $25
Sep-21-15Upgrade JMP Securities Mkt Perform → Mkt Outperform
May-22-15Initiated ROTH Capital Buy $13
Nov-17-17 11:55AM  Why Vascular Biogenics Ltd. Is Tanking Today Motley Fool -23.89%
10:36AM  Heres Why Vascular Biogenics Ltd (VBLT) Stock Is Slumping Today SmarterAnalyst
09:00AM  VBL Therapeutics Prices  2.5 Million Ordinary Share Offering GlobeNewswire
Nov-16-17 04:01PM  VBL Therapeutics Announces Proposed Public Offering of 2.5 Million Shares of Ordinary Shares GlobeNewswire +17.26%
Nov-15-17 03:04AM  Edited Transcript of VBLT earnings conference call or presentation 14-Nov-17 1:30pm GMT Thomson Reuters StreetEvents -11.78%
Nov-14-17 07:23AM  Vascular Biogenics reports 3Q loss Associated Press +10.13%
07:00AM  VBL Therapeutics Announces Third Quarter 2017 Financial Results GlobeNewswire
06:30AM  Vascular Biogenics Ltd. to Host Earnings Call ACCESSWIRE
Nov-13-17 07:28PM  Who Are The Major Shareholders Of Vascular Biogenics Ltd (VBLT)? Simply Wall St.
Nov-09-17 08:00AM  VBL Therapeutics to Present at the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) on November 18 GlobeNewswire
Nov-07-17 10:29AM  VBL Therapeutics to Report Third Quarter 2017 Results on November 14 GlobeNewswire +5.43%
Nov-06-17 07:00AM  VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan GlobeNewswire
Oct-23-17 08:05AM  VBL Therapeutics Celebrates Opening of its New Gene Therapy Manufacturing Plant and Company Headquarters GlobeNewswire
Oct-20-17 07:00AM  VBL Therapeutics Announces Orphan Drug Designation for VB-111 in Europe GlobeNewswire
Oct-02-17 07:00AM  VBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in Recurrent GBM GlobeNewswire
Sep-28-17 07:00AM  VBL Therapeutics to Present at the Chardan Gene Therapy Conference GlobeNewswire
Sep-14-17 08:00AM  VBL Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26th in New York GlobeNewswire
Aug-28-17 08:00AM  VBL Therapeutics to Present at the Rodman & Renshaw Global Investment Conference in New York on September 10-12, 2017 GlobeNewswire
Aug-16-17 08:30AM  Strength Seen in Vascular Biogenics (VBLT): Stock Jumps 5.3% Zacks
Aug-15-17 12:33PM  Edited Transcript of VBLT earnings conference call or presentation 14-Aug-17 12:30pm GMT Thomson Reuters StreetEvents +5.38%
Aug-14-17 10:21PM  Vascular Biogenics reports 2Q loss Associated Press +12.05%
07:00AM  VBL Therapeutics Announces Second Quarter 2017 Financial Results GlobeNewswire
06:00AM  Investor Network: Vascular Biogenics Ltd. to Host Earnings Call ACCESSWIRE
Aug-02-17 08:00AM  VBL Therapeutics to Report Second Quarter 2017 Results on August 14 GlobeNewswire
Jun-19-17 08:00AM  VBL Therapeutics Provides Update on Long-Term Survival in Phase 2 Trials of Patients with Multiple Tumor Types GlobeNewswire +9.89%
Jun-15-17 07:00AM  VBL Therapeutics Announces Appointment of Dr. Corinne Epperly as U.S. Chief Operating Officer GlobeNewswire
Jun-14-17 08:00AM  VBL Therapeutics to Present at Upcoming June Conferences GlobeNewswire
Jun-08-17 07:00AM  VBL Therapeutics Awarded $2.5 Million Grant by the Israel Innovation Authority GlobeNewswire
Jun-05-17 07:30AM  New Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM GlobeNewswire
May-15-17 07:20AM  Vascular Biogenics reports 1Q loss Associated Press
07:15AM  VBL Therapeutics Announces First Quarter 2017 Financial Results GlobeNewswire
07:00AM  Investor Network: Vascular Biogenics Ltd. to Host Earnings Call Accesswire
May-11-17 07:00AM  VBL Therapeutics Presents Data on VB-111 in Combination with Checkpoint Inhibitor at the 20th Annual ASGCT Meeting GlobeNewswire
May-03-17 08:00AM  VBL Therapeutics to Report First Quarter 2017 Results on May 15 GlobeNewswire
Apr-25-17 07:00AM  VBL Therapeutics Announces Upcoming Presentations on VB-111 at the ASCO and ASGCT 2017 Conferences GlobeNewswire
Apr-24-17 04:21PM  3 Different Companies, 3 Different Approaches to Tumors GuruFocus.com
Apr-20-17 04:01PM  VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM GlobeNewswire
Apr-04-17 07:00AM  VBL Therapeutics Presents Data on MOSPD2, a Novel Immuno-Oncology Target GlobeNewswire
07:00AM  VBL Therapeutics Presents Data on MOSPD2, a Novel Immuno-Oncology Target
Apr-03-17 07:00AM  VBL Therapeutics Presents New Data Supporting Use of Lecinoxoids in NASH GlobeNewswire
Mar-30-17 01:04PM  VASCULAR BIOGENICS LTD. Financials
Mar-28-17 07:00AM  VBL Therapeutics to Present at the H.C. Wainwright NASH Investor Conference GlobeNewswire
Mar-27-17 07:30PM  Edited Transcript of VBLT earnings conference call or presentation 27-Mar-17 12:30pm GMT Thomson Reuters StreetEvents
07:30PM  Edited Transcript of VBLT earnings conference call or presentation 27-Mar-17 12:30pm GMT
08:30AM  Vascular Biogenics Ltd Earnings Call scheduled for 8:30 am ET today
07:30AM  VBL Therapeutics Announces Fourth Quarter and Year End 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 Vascular Biogenics Ltd Earnings Release - Before Market Open
Mar-23-17 07:00AM  VBL Therapeutics to Host a Key Opinion Leader Event on Novel New Targets and Immunotherapeutic Approaches to Oncology GlobeNewswire +23.33%
Mar-15-17 07:00AM  VBL Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference GlobeNewswire
Mar-07-17 07:00AM  VBL Therapeutics to Present at the 29th Annual ROTH Conference GlobeNewswire
Mar-02-17 08:00AM  VBL Therapeutics to Report Full-Year 2016 Financial Results on March 27 GlobeNewswire
Feb-22-17 10:05AM  VBL Therapeutics Thyroid Cancer Drug Clears Phase 2 Investopedia
10:05AM  VBL Therapeutics Thyroid Cancer Drug Clears Phase 2 at Investopedia
Feb-21-17 07:00AM  VBL Therapeutics Reports Full Data for VB-111 Monotherapy in Phase 2 Trial for Recurrent Thyroid Cancer GlobeNewswire
Feb-06-17 08:00AM  VBL Therapeutics to Present at the 2017 BIO CEO & Investor Conference GlobeNewswire
Jan-31-17 04:01PM  VBL Therapeutics Announces Publication of Research on a Potential Novel Immuno-Oncology Target GlobeNewswire
Jan-09-17 07:00AM  VBL Therapeutics Provides Year End 2016 Corporate Update GlobeNewswire
Jan-06-17 07:00AM  VBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE Study GlobeNewswire
Dec-20-16 12:03AM  How Xenon Pharmaceuticals Inc (XENE) Stacks Up Against Its Peers at Insider Monkey
Dec-05-16 07:00AM  VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM GlobeNewswire
Dec-01-16 08:35AM  Vascular Biogenics Ltd. :VBLT-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
Nov-29-16 07:00AM  VBL Therapeutics Announces Overall Survival Data for VB-111 Monotherapy in Phase 2 Study for Recurrent Thyroid Cancer GlobeNewswire +13.00%
Nov-23-16 10:51AM  VBL Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29 GlobeNewswire
Nov-10-16 08:30AM  Vascular Biogenics Ltd Earnings Call scheduled for 8:30 am ET today -7.69%
08:19AM  Vascular Biogenics reports 3Q loss
07:00AM  VBL Therapeutics Announces Third Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
Nov-02-16 08:00AM  VBL Therapeutics to Report Third Quarter 2016 Financial Results on November 10 GlobeNewswire
Oct-13-16 09:04AM  VBL Therapeutics Announces Plans to Establish New Manufacturing Facility GlobeNewswire
Sep-14-16 08:37AM  Earnings Estimates Moving Higher for Vascular Biogenics (VBLT): Time to Buy?
Sep-08-16 09:21AM  5 Stocks Under $10 That Could Make You a Lot of Money
Sep-06-16 08:00AM  VBL Therapeutics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 12th, 2016 GlobeNewswire
Aug-15-16 07:22AM  Vascular Biogenics reports 2Q loss -5.36%
07:00AM  VBL Therapeutics Announces Second Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
Aug-11-16 06:45AM  BioLineRx Names Philip A. Serlin as Chief Executive Officer PR Newswire
Jul-26-16 08:15AM  VBL Therapeutics to Report Second Quarter 2016 Financial Results on August 15 GlobeNewswire
Jul-20-16 07:11AM  Trade These 7 Stocks Under $10 for Huge Profits
Jul-02-16 10:01AM  7 Analyst Stock Picks Under $10 With Massive Upside Calls at 24/7 Wall St.
Jun-28-16 07:07AM  Coverage initiated on VBL Therapeutics by H.C. Wainwright
Jun-27-16 11:33AM  Why Registered Direct Offerings Are Like Insider Proxies, 3 Stocks in Point at Insider Monkey
Jun-21-16 07:00AM  VBL Therapeutics Announces Appointment of Dr. Rachel W. Humphrey to Head of the Scientific Advisory Board GlobeNewswire
Jun-16-16 10:40AM  Vascular Biogenics Ltd. Closes $24 Million Registered Direct Offering GlobeNewswire +13.90%
Jun-08-16 06:02PM  Vascular Biogenics Ltd. :VBLT-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -12.65%
Jun-07-16 08:00AM  VBL Therapeutics to Present Today at the 2016 BIO International Convention GlobeNewswire -14.60%
07:44AM  Vascular Biogenics Ltd. Announces $24 Million Registered Direct Offering GlobeNewswire
Jun-06-16 11:21AM  Heres Why These Five Stocks Are Surging Today at Insider Monkey +72.54%
10:59AM  Vascular Biogenics (VBLT) Stock Spikes on Positive Trial Results
08:55AM  Why Vascular Biogenics Is One of the Biggest Winners From ASCO So Far at 24/7 Wall St.
08:40AM  Vascular Biogenics stock up 34% in pre-market trade after positive cancer drug trial results at MarketWatch
07:00AM  VB-111 Clinical Data Presented at ASCO Demonstrate Significant Increase in Overall Survival in Platinum-Resistant Ovarian Cancer GlobeNewswire
Jun-03-16 04:02PM  Clinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin® Meta-analysis Data GlobeNewswire
May-20-16 05:22PM  Edited Transcript of VBLT earnings conference call or presentation 13-May-16 12:30pm GMT
May-13-16 08:07AM  Vascular Biogenics reports 1Q loss
08:00AM  VBL Therapeutics Announces First Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
May-09-16 08:52AM  Akers Biosciences (AKER) Q1 Earnings: What's in Store? Zacks
May-05-16 04:02PM  VBL Therapeutics to Report First Quarter 2016 Financial Results on May 13 GlobeNewswire
May-03-16 11:02AM  VBL Therapeutics Announces Clinical Data to be Presented at 2016 ASCO Annual Meeting GlobeNewswire +13.50%
Apr-27-16 08:00AM  VBL Therapeutics to Host Key Opinion Leader Meeting on Wednesday, May 4 in New York City GlobeNewswire
Apr-19-16 08:00AM  VBL Therapeutics Announces Publication of NASH Data for Lecinoxoids Molecules VB-201 and VB-703 GlobeNewswire
Mar-29-16 02:43PM  Edited Transcript of VBLT earnings conference call or presentation 29-Mar-16 12:30pm GMT -8.09%
08:17AM  VBL Therapeutics Announces Full-Year 2015 Financial Results and Provides Business Update at noodls
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, is engaged in the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead product candidates include VB-111, a gene-based biologic, which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; in Phase II clinical trials to treat thyroid cancer; and in Phase I/II clinical trials for the treatment of ovarian cancer, as well as VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Or Yehuda, Israel.